A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)

Name: A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
Published: 2023
License: Public Domain

AstraZeneca · 2023

ClinicalTrials.gov · Datasets · License: Public Domain · 2023

Open Source ↗

breast-cancer paclitaxel

breast cancer, triple-negative, metastatic, inoperable, datopotamab deruxtecan, dato-dxd, ds1062a, ds1062, durvalumab, paclitaxel, nab-paclitaxel, gemcitabine

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Record · ID 914637
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.